Promising bioadhesive ofloxacin-loaded polymeric nanoparticles for the treatment of ocular inflammation: formulation and in vivo evaluation

Bibliographic Information
Authors: Salama A.H.; AbouSamra M.M.; Awad G.E.A.; Mansy S.S.
Journal: Drug Delivery and Translational Research
Publisher: Springer
Publication Date: 2 October 2020
Volume / Issue: Volume 11 / Issue 5
Pages: 1943–1957
ISSN: 2190393X
DOI: 10.1007/s13346-020-00856-8
Scopus: View on Scopus
PubMed: 33006742
Document Type: Article
Authors and Affiliations
Salama A.H., Pharmaceutical Technology Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 El-Buhouth Street, Dokki, Cairo, 12622, Egypt, Department of Pharmaceutics, Faculty of Pharmacy, Ahram Canadian University, 6th of October City, Cairo, Egypt; AbouSamra M.M., Pharmaceutical Technology Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 El-Buhouth Street, Dokki, Cairo, 12622, Egypt; Awad G.E.A., Chemistry of Natural and Microbial Product Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Cairo, 12622, Egypt; Mansy S.S., Electron Microscopy Research Department, Theodor Bilharz Research Institute, Cairo, Egypt
Abstract
Abstract: Our work tackles the combined advantages of both nanotechnology and the bioadhesive gel properties which were utilized to design an ocular drug delivery system that is capable to treat ocular inflammation. Nanoparticles encapsulating an antibiotic drug, ofloxacin, were fabricated using emulsion solvent evaporation technique adopting 23 full factorial design to evaluate the effect of formulation parameters: that is to say, the molecular weight of the polymer (polycaprolactone), amount of Kolliphor P188, and presence of the charge inducer (chitosan hydrochloride) on the measured responses: drug entrapment efficiency (EE%), particle size (PS), polydispersity index (PDI) and zeta potential (ZP). The results show that the optimized LPCL-NP2 formulation (composed of low molecular weight polycaprolactone, 500 mg of Kolliphor P188, 0.25% chitosan hydrochloride, and 50 mg ofloxacin) displayed a sphere shape with EE%, PS, PDI, and ZP values of 89.73 ± 0.04%, 195.4 ± 13.17 nm, 0.323 ± 0.01, and 55.4 ± 0.66 mV, respectively. DSC study confirmed the amorphous nature of the drug. The optimized nanoparticle formulation was then further incorporated into the following two ocular formulations: gel (LPCL-NP2-G4) and in situ forming gel (LPCL-NP2-ISG4). The penetration of optimized ocular formulations was assessed by confocal laser scanning microscopy. The antimicrobial study was conducted for the following three ocular formulations: LPCL-NP2 presented as eye drops, LPCL-NP2-G4, and LPCL-NP2-ISG4 as well as the market product using rabbits which were infected in their eyes with Escherichia coli. Results revealed that rabbits treated with LPCL-NP2-ISG4 demonstrated a remarkable antibacterial efficacy and evident low bacterial growth which was additionally assured by the histopathological examination of eye biopsies compared with the other investigated groups. Thus, a novel ofloxacin-loaded nanoparticle formulation based on polycaprolactone is presented in the form of mucoadhesive non-irritating in situ forming ocular gel possessing a superior antibacterial activity. [Figure not available: see fulltext.] © 2020, Controlled Release Society.
Keywords
Confocal laser scanning microscopy; Mucoadhesive; Nanoparticles; Ocular drug delivery; Ofloxacin; Polycaprolactone; Animals; Chitosan; Drug Carriers; Drug Delivery Systems; Inflammation; Particle Size; Rabbits; polymer nanoparticle; drug carrier; nanoparticle; animal experiment; animal model; animal tissue; antibacterial activity; Article; controlled study; differential scanning calorimetry; dispersity; drug formulation; Escherichia coli; ex vivo study; eye biopsy; eye inflammation; factorial design; histopathology; human; in vitro study; in vivo study; male; molecular weight; mouse; nonhuman; zeta potential; animal; drug delivery system; Leporidae
Citation Information
Scopus Citations: 37
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
